Detalhe da pesquisa
1.
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Lancet Oncol
; 19(11): 1459-1467, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30348537
2.
PEG tube dependency after prophylactic placement in 209 head and neck cancer patients treated with chemoradiotherapy or radiation with cetuximab.
Clin Otolaryngol
; 44(2): 172-175, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30615256
3.
Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.
Head Neck
; 42(5): 828-838, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31903657
4.
A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
Eur J Cancer
; 107: 60-67, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30544060
5.
Painful ophthalmoplegia from metastatic nonproducing parathyroid carcinoma: case study and review of the literature.
Neuro Oncol
; 4(1): 44-8, 2002 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-11772432
6.
Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Oncol Nurs Forum
; 36(2): 225-31, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19273412